

**BEST AVAILABLE COPY**  
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 July 2003 (31.07.2003)

PCT

(10) International Publication Number  
**WO 03/061728 A2**

- (51) International Patent Classification<sup>7</sup>: **A61M**
- (21) International Application Number: PCT/US03/01596
- (22) International Filing Date: 16 January 2003 (16.01.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/349,658 16 January 2002 (16.01.2002) US
- (71) Applicant: **PEPGEN CORPORATION** [US/US]; Suite B, 1255 Harbor Bay Parkway, Alameda, CA 94502 (US).
- (72) Inventors: **SOKAWA, Yoshihiro**; Department of Bio-Technology, Kyoto Institute of Technology, Kyoto 606 (JP). **LIU, Chih-Ping**; 1483 Sutter Street #1705, San Francisco, CA 94109 (US).
- (74) Agents: **MOHR, Judy, M.** et al.; Perkins Coie LLP, P.O. Box 2168, Menlo Park, CA 94026 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 03/061728 A2**

FIG 1

14

(54) Title: ORAL ADMINISTRATION OF INTERFERON-TAU

(57) Abstract: A method of administering interferon- $\tau$  to a subject subsequent to a defined food and/or water intake regimen is described. The method comprises administering orally to the subject, subsequent to fasting and/or fasting combined with a controlled or absence of fluid intake, an amount of interferon- $\tau$  that is effective to achieve an increased level of 2'5'-oligoadenylate synthetase (OAS) activity in whole blood relative to that achieved from oral administration to a subject also treated with interferon- $\tau$  but not held to the defined food and/or water intake regimen.

## **ORAL ADMINISTRATION OF INTERFERON-TAU**

### **Field of the Invention**

The present invention relates generally to oral delivery of cytokines and  
5 more particularly to oral delivery of interferons.

### **Background**

In recent years, the variety of therapeutic agents for treatment of  
physiological conditions and disease states has expanded considerably, due in  
10 large part to the growing use of polypeptides and proteins as therapeutic agents.  
The important role of peptides in replacement therapy and as pharmaceutical  
agents is reflected in the efforts toward synthesis of large quantities of proteins by  
recombinant DNA technology.

One limiting factor in the use of proteins and polypeptides as therapeutic  
15 agents is metabolism by plasma proteins when given parenterally. The oral  
route of administration is even more problematic due to proteolysis in the  
stomach, where the acidic conditions can destroy the molecule before reaching its  
intended target. For example, polypeptides and protein fragments, produced by  
action of gastric and pancreatic enzymes, are cleaved by exo- and  
20 endopeptidases in the intestinal brush border membrane to yield di- and tri-  
peptides. If proteolysis by pancreatic enzymes is avoided, polypeptides are  
subject to degradation by brush border peptidases. Polypeptides or proteins that  
might survive passage through the stomach are subject to metabolism in the  
intestinal mucosa where a penetration barrier prevents entry into cells.

25 Despite these obstacles, therapeutically beneficial oral delivery of proteins  
and polypeptides can be achieved, typically by formulating the molecule in a  
protective dosage form for survival in the stomach and intestines until absorbed by  
the intestinal mucosa. For example, the protein can be co-administered with  
protease inhibitors, stabilized with polymeric materials, or encapsulated in a lipid  
30 or polymer particle. Another approach is to avoid the gastrointestinal tract  
altogether, by delivering the protein to the oral-pharyngeal region in the form of a  
lozenge or solution held in the oral cavity for a period of time.

Another factor that must be considered in oral administration of compounds  
are food-drug interactions that may alter the pharmacokinetics and

pharmacodynamic profile of the orally administered drug. Food effects on drug absorption and bioavailability have been studied for small drug molecules (see for example, Singh, B., *Clin. Pharmacokinet* 37(3):213, (1999)), but less is known about food effects on absorption and bioavailability of proteins and peptides and it is not clear that the mechanisms for smaller drug compounds apply to proteins and peptides. Even for small drug compounds, it is unknown *a priori* what effect stomach contents will have on the compound. There are typically five categories of food effects on absorption of small drug molecules: those causing (1) decreased (2) delayed; (3) increased; or (4) accelerated absorption, and (5) those in which food has no significant effect. There are a number of variables that interface between differential effects of food and postprandial bioavailability are (i) the physicochemical characteristics and composition of the drug; (ii) timing of the meal in relation to time of drug administration; (iii) size and composition of meals; and (iv) dosage. Further, the mechanism of "food effect" may involve physiological and sensory responses to food, such as changes in gastro-intestinal milieu and gastric emptying rate, and reflux action (*Id.*)

Although there is a vast amount of literature on food effects on small drug compounds, there is still no basis to predict the effect of food for a particular chemical entity or a chemical class of therapeutic agents (*Id.*). Moreover, there is no basis for knowing if the studies on small drug compounds are applicable to proteins and polypeptides; and even if they are, there is simply no way to know what effect food and/or water intake will have on an orally administered non-native protein like interferon-tau.

Interferon-tau (hereinafter "IFN- $\tau$ " or interferon- $\tau$ ) was discovered originally as a pregnancy recognition hormone produced by the trophectoderm of ruminant conceptuses (Imakawa, K., *et al*, *Nature* 330:377-379, (1987); Bazer, F.W. and Johnson, H.M., *Am J Repro Immunol* 26:19-22, (1991)). Although the distribution of the IFN- $\tau$  gene is restricted to ruminants including cattle, sheep, and goats, (Alexenko, A.P., *et al.*, *J Interferon and Cytokine Res* 19:1335-1341, (1999)) IFN- $\tau$  exhibits activity in cells belonging to other species including humans and mice (Pontzer, C.H., *et al.*, *Cancer Res* 51:5304-5307, (1991); Alexenko, A.P., *et al.*, *J Interferon and Cytokine Res* 20:817-822, (2000)). For example, IFN- $\tau$  has been demonstrated to possess antiviral, (Pontzer, C.H., *et al.*, *Biochem Biophys Res*

*Commun* 152:801-807, (1988)), antiproliferative, (Pontzer, C.H., *et al.*, 1991) and immunoregulatory activities (Assal-Meliani, A., *Am J Repro Immunol* 33:267-275, (1995)).

While IFN- $\tau$  displays many of the activities classically associated with type I IFNs, such as interferon- $\alpha$  and interferon- $\beta$ , considerable differences exist between IFN- $\tau$  and the other type I IFNs. The most prominent difference is the role of IFN- $\tau$  in pregnancy in ruminant species. The other IFNs have no similar activity in pregnancy recognition. Also different is viral induction. All type I IFNs, except IFN- $\tau$ , are induced readily by virus and dsRNA (Roberts, *et al.*, *Endocrine Reviews* 13:432 (1992)). Induced IFN- $\alpha$  and IFN- $\beta$  expression is transient, lasting approximately a few hours. In contrast, IFN- $\tau$  synthesis, once induced, is maintained over a period of days (Godkin, *et al.*, *J. Reprod Fert.* 65:141 (1982)). On a per-cell basis, 300-fold more IFN- $\tau$  is produced than other type I IFNs (Cross, J.C. and Roberts, R.M., *Proc. Natl. Acad. Sci. USA* 88:3817-3821 (1991)).

Another difference lies in the amino acid sequences of IFN- $\tau$  and other type I interferons. The percent amino acid sequence similarity between the interferons  $\alpha_{2b}$ ,  $\beta_1$ ,  $\omega_1$ ,  $\gamma$ , and  $\tau$  are summarized in the table below.

	rHuIFN $\alpha_{2b}$	rHuIFN $\beta_1$	rHuIFN $\omega_1$	rHuIFN $\gamma$	rOvIFN $\tau$
RhuIFN $\alpha_{2b}$		33.1	60.8	11.6	48.8
RhuIFN $\beta_1$	33.1		33.1	12.2	33.8
RhuIFN $\omega_1$	60.8	33.1		10.2	54.9
RhuIFN $\gamma$	11.6	12.2	10.2		10.2
rOvIFN $\tau$	48.8	33.8	54.9	10.2	

Sequence comparison determined from the following references:

Taniguchi *et al.*, *Gene*, 10(1):11 (1980).

Adolf *et al.*, *Biochim. Biophys. Acta*, 1089(2):167 (1991).

Streuli *et al.*, *Science*, 209:1343 (1980).

Imakawa *et al.*, *Nature*, 330:377 (1987).

Recombinant ovine IFN $\tau$  (rOvIFN $\tau$ ) is 48.8 percent homologous to IFN $\alpha_{2b}$  and 33.8 percent homologous to IFN $\beta_1$ . Because of this limited homology between IFN $\tau$  and IFN $\alpha$  and between IFN $\tau$  and IFN $\beta$ , it cannot be predicted whether or not IFN $\tau$  would behave in the same manner as IFN $\alpha$  or IFN $\beta$  when administered orally. Teachings in the art relating to oral administration of IFN $\alpha$ ,

IFN $\beta$ , or any other non-tau interferon, fail to provide a basis for drawing any expectations for IFN- $\tau$ .

### Summary of the Invention

5 Accordingly, in one aspect the invention includes a method of administering interferon- $\tau$  to a subject subsequent to a defined food and/or water intake regimen. The method comprises administering orally to the subject an amount of interferon- $\tau$  that is effective to achieve an increased level of 2',5'-oligoadenylate synthetase (OAS) activity in whole blood relative to that achieved from oral  
10 administration to a subject also treated with interferon- $\tau$  but not held to a defined food and/or water intake regimen.

In one embodiment, the interferon- $\tau$  is ovine or bovine interferon- $\tau$ .

The interferon- $\tau$  can be administered in the form of a solid dosage form or as a liquid dosage form. An exemplary dosage is of at least about  $1 \times 10^4$   
15 Units/day.

In another aspect, the invention contemplates a method administering interferon- $\tau$ , comprising (i) withholding food from a subject selected for administration of interferon- $\tau$ ; and (ii) orally administering interferon- $\tau$  to the subject to achieve an increased level of 2',5'-oligoadenylate synthetase in the  
20 blood relative to the level of 2',5'-oligoadenylate synthetase in the blood obtained after oral administration of interferon- $\tau$  to a fed subject.

In one embodiment, withholding further includes withholding water from the subject. In another embodiment, withholding comprises withholding food from the subject for at least one hour, more preferably, for at least four hours, still more  
25 preferably for at least six hours, prior to oral administration.

The method of the invention, in another embodiment, finds use in treating an autoimmune condition, a viral infection, or a condition associated with cellular proliferation.

In yet another aspect, an improvement in a method of oral administration of  
30 interferon- $\tau$  is contemplated. The improvement comprises withholding food from a subject prior to oral administration of IFN- $\tau$  to the subject. Such withholding is effective to achieve an increased level of 2',5'-oligoadenylate synthetase in the

blood relative to the level of 2',5'-oligoadenylate synthetase in the blood obtained after oral administration of interferon- $\tau$  to a fed subject.

These and other objects and features of the invention will become more fully apparent when the following detailed description is read in conjunction with the accompanying drawings.

### **Brief Description of the Drawings**

Figs. 1A-1D are bar graphs showing the effect of fasting conditions on the induction of blood OAS in mice by administration of OvIFN- $\tau$ . The induction of blood OAS is shown as a percentage of control, taken as blood OAS in mice treated with a solution of 10% maltose without interferon. Treated mice received  $10^4$  U of OvIFN $\tau$  (via intraperitoneal injection or oral administration) six hours after the indicated intake regimen: Fig. 1A, no food and no water; Fig. 1B, water without food; Fig. 1C, food without water; Fig. 1D, both food and water. Each bar represents the average  $\pm$  S.E. of one experiment (3 mice) of two performed, with similar results.

Fig. 2 is a bar graph showing blood OAS concentration, in pmol/dL, in several mouse strains (ICR, BALB/c, C57BL, NZW/N and SJL/J) following peroral administration of OvIFN- $\tau$  ( $10^5$  U). Control mice received orally a solution of 10% maltose without IFN. Each bar represents the average  $\pm$  S.E. of one experiment (3~5 mice) of two performed, with similar results.

Figs 3A-3B are bar graphs showing induction of blood OAS activity in mice after administration of OvIFN $\tau$  following a 6 hour fast. IFN $\tau$  was administered orally or via intraperitoneal injection. Fig. 3A shows blood OAS levels, expressed as a percentage of control (see description in Fig. 1 above) in blood samples taken at time zero and at 8 hours, 16 hours, and 24 hours post IFN $\tau$  ( $10^5$  U) administration. Fig. 3B shows blood OAS levels, expressed as a percentage of control, 24 hours after delivery of OvIFN $\tau$  at concentrations of 0,  $10^2$ ,  $10^3$ ,  $10^4$ , and  $10^5$  U. Each bar represents the average  $\pm$  S.E. of one experiment (3 mice) of two performed, with similar results.

Fig. 4 is a bar graph showing induction of blood OAS activity, expressed as a percentage of control (see description of control in Fig. 1 above), by administration of MuIFN $\alpha$  (0,  $10^2$ ,  $10^3$  and  $10^4$  IU) given to ICR mice by orally or

via intraperitoneal injection. The OAS activity in blood was assayed 16 hours after IFN $\alpha$  administration. Each bar represents the average  $\pm$  S.E. of one experiment (3 mice) of two performed, with similar results.

5

### **Brief Description of the Sequences**

SEQ ID NO:1 is the nucleotide sequence of a synthetic gene encoding ovine interferon- $\tau$ . Also shown is the encoded amino acid sequence.

SEQ ID NO:2 is an amino acid sequence of a mature OvIFN- $\tau$  protein.

10

### **Detailed Description of Invention**

#### **I. Definitions**

"Fasted state" or "fasting conditions" intend abstaining from all food and drinking only water for at least about one hour, preferably for at least about two hours, more preferably for at least about four hours, most preferably for at least  
15 about six hours, prior to oral administration of a therapeutic agent, such as a protein or peptide.

"Fasted state also excluding water" intends abstaining from all food and all fluids, including but not limited to water, for at least about one hour, preferably for at least about two hours, more preferably for at least about four hours, most  
20 preferably for at least about six hours, prior to oral administration of a therapeutic agent, such as a protein or peptide.

"Non-fasted state" or "fed state" intend consumption of food and/or water at any time prior to oral administration of a therapeutic agent, such as a protein or peptide.

25 "Withholding food" intends a fasted state.

"Orally administering" or "oral administration" intend delivery of a compound to the stomach and/or gastro-intestinal system of a subject. These terms do not include oral-pharyngeal delivery, where systemic delivery of a compound is achieved by absorption in the oral cavity or pharyngeal area.

30 "Peptide" and "polypeptide" are used interchangeably herein and refer to a compound made up of a chain of amino acid residues linked by peptide bonds. Unless otherwise indicated, the sequence for peptides is given in the order from the amino terminus to the carboxyl terminus.

When a first peptide or polypeptide is said to "correspond" or to be "homologous" to a second peptide or polypeptide fragment, it means that the peptide or fragments have a similarity in amino acid residues if they have an alignment score of >5 (in standard deviation units) using the program ALIGN with the mutation gap matrix and a gap penalty of 6 or greater (Dayhoff, M. O., in 5 ATLAS OF PROTEIN SEQUENCE AND STRUCTURE (1972) Vol. 5, National Biomedical Research Foundation, pp. 101-110, and Supplement 2 to this volume, pp. 1-10.) The two sequences (or parts thereof) are more preferably homologous if their amino acids are greater than or equal to 50%, more preferably 70%, still more preferably 80%, identical when optimally aligned using the ALIGN program 10 mentioned above.

A polypeptide sequence or fragment is "derived" from another polypeptide sequence or fragment when it has an identical sequence of amino acid residues as a region of the another sequence or fragment.

15 An *interferon- $\tau$*  polypeptide is a polypeptide having between about 15 and 172 amino acids derived from an interferon- $\tau$  amino acid coding sequence, where said 15 to 172 amino acids are contiguous in native interferon- $\tau$ . Such 15-172 amino acid regions can also be assembled into polypeptides where two or more such interferon- $\tau$  regions are joined that are normally discontinuous in the native 20 protein.

*Treating* a disease refers to administering a therapeutic substance effective to reduce the symptoms of the disease and/or lessen the severity of the disease.

## 25 II. Method of Interferon Administration

### A. Interferon- $\tau$

The 172 amino acid sequence of ovine-IFN $\tau$  is set forth, for example, in U.S. Patent No. 5,958,402, and is also set forth herein as SEQ ID NO:2. IFN $\tau$  sequences with similar characteristics and activities to ovine IFN- $\tau$  have been isolated from other ruminant species including cows and goats (Bartol, F.F., *et al.*, 30 *Biol. Reprod.* 32:681-693, (1985); Gnatek, G.G., *et al.*, *Biol. Reprod.* 41:655-664, (1989); Helmer, S.D., *et al.*, *J. Reprod. Fert.* 79:83-91, (1987); and Imakawa, K., *et al.*, *Mol. Endocrinol.* 3:127, (1989)). Bovine IFN $\tau$  (BoIFN $\tau$ ) and OvIFN $\tau$  (i) have similar functions in maternal recognition of pregnancy, and (ii) share a high degree



of amino acid and nucleotide sequence homology between mature proteins. The nucleic acid sequence homology between OvIFN $\tau$  and BoIFN $\tau$  is 76.3% for the 5' non-coding region, 89.7% for the coding region, and 91.9% for the 3' non-coding region. The amino acid sequence homology is 80.4%. The homologous bovine-IFN $\tau$  sequence is described, for example, in Helmer *et al.*, *J. Reprod. Fert.* **79**:83-91, (1987) and Imakawa, K. *et al.*, *Mol. Endocrinol.* **3**:127, (1989). The sequences of ovine-IFN $\tau$  and bovine-IFN $\tau$  from these references are hereby incorporated by reference.

#### B. Method of Administration

In studies performed in support of the invention, OvIFN- $\tau$  was administered orally to mice and the induction of 2',5'-oligoadenylate synthetase (OAS) activity, a recognized marker of IFN action (Shindo, M., *et al.*, *Hepatology* **8**:366-370, (1988)), in whole blood was monitored. In all of the studies describe below; the procedure set forth in Example 1 was followed. Before administration of OvIFN- $\tau$ , mice were deprived of food and drink for at least six hours and IFN- $\tau$  was given by peroral (p.o.) administration and, for a comparative control, by intraperitoneal (i.p.) injection. When administered orally, IFN- $\tau$  was introduced directly into the upper part of the stomach using an oral feeding needle.

In an initial study, the effect of fasting conditions on the induction of blood OAS in mice by administration of OvIFN- $\tau$  was evaluated. In this study, mice were subjected to a defined food and water intake regimen for six hours. After the six hour regimen,  $10^4$  U of OvIFN $\tau$  was administered by oral gavage or by intraperitoneal injection, along with food and water. The intake regimens were as follows: Case I, neither food nor water was given; Case II, water but no food was given; Case III, only food was given; Case IV, both food and water were given. Whole blood was obtained from the heart at 24 hours and levels of OAS activity were determined. The results are shown in Figs. 1A-1D.

Figs. 1A-1D correspond to the mice subjected to Case I-Case IV food and water intake regimens defined in the paragraph above, respectively. The results in Figs. 1A-1D are show the induction of blood OAS expressed as a percentage of control, taken as blood OAS in mice treated with a solution of 10% maltose without interferon. The results show that higher blood OAS levels are induced by

oral administration of IFN- $\tau$  to subjects in a fasted state, as seen best in Fig. 1A and Fig. 1B for mice receiving no food.

In this study, it was observed that almost the same amounts of food were ingested with or without a supply of water. Water intake, however, was lower without food (case I and case II) than with food (case III and case IV). In some animals, after fasting for six hours, a 0.2-ml maltose solution containing blue dye was given orally and the distribution of the dye in the stomach and intestine was examined (data not shown). Following the ingestion of food (case III and case IV), the stomachs of mice swelled and the dye localized mainly in the stomach, probably because the food absorbed the dye. However, the dye was transferred quickly to the intestine when no food was ingested. This observation suggests that OvIFN- $\tau$  taken orally may exert its effect in the intestine to induce high levels of OAS activity in blood.

Fig. 2 shows the effects of gastric administration of OvIFN- $\tau$  on the induction of OAS activity in blood in a variety of mouse strains: ICR, BALB/c, C57BL/9, NZW/N and SJL/J. All test mice were treated orally with OvIFN- $\tau$  ( $10^5$  U). Control mice received orally a solution of 10% maltose without IFN- $\tau$ . Each bar represents the average  $\pm$  S.E. of one experiment (3~5 mice) of two performed, with similar results.

As seen in Fig. 2, the level of OAS activity in all mouse strains increased following peroral administration of OvIFN- $\tau$ , though the extent of the increase varied with the strain. The level of activity induced in ICR, C57BL/9 and NZW/N mice was higher than that in BALB/c and SJL/J mice.

In another study, OAS activity was monitored as a function of time after administration of IFN- $\tau$ . In this study, animals (ICR mice) were subjected to a six hour fast (water but no food) prior to administration of IFN- $\tau$  ( $10^5$ U). Blood was sampled at 8 hours, 16 hours, and 24 hours post IFN- $\tau$  administration. The results are shown in Fig. 3A.

Fig. 3A shows blood OAS levels, expressed as a percentage of control (see description in Fig. 1 above), in blood samples taken at the indicated time intervals post IFN $\tau$  administration. In Fig. 3A, each bar represents the average  $\pm$  S.E. of one experiment (3 mice) of two performed, with similar results. OAS activity in whole blood increased in a time-dependent manner regardless of the route, oral or

i.p. injection, however, a higher level was observed at the 24 hour time point after oral administration than i.p. injection.

In another study, OvIFN- $\tau$  at varying concentrations (0,  $10^2$ ,  $10^3$ ,  $10^4$  and  $10^5$  U), was given to mice following a six hour fast. Blood was obtained after 24 hours, and OAS activity was assayed. The results are shown in Fig. 3B.

Fig. 3B shows blood OAS levels, expressed as a percentage of control (see control description in Fig. 1 above), 24 hours after delivery of OvIFN $\tau$  at concentrations of 0,  $10^2$ ,  $10^3$ ,  $10^4$ , and  $10^5$  U. Each bar represents the average  $\pm$  S.E. of one experiment (3 mice) of two performed, with similar results. Following i.p. injection, the level of activity was rather high at a low dose ( $10^2$  U), and saturated at higher doses of OvIFN- $\tau$  ( $10^4$  and  $10^5$  U). In contrast, the level of activity after p.o. administration increased dose-dependently.

The data in Figs. 3A-3B shows that IFN- $\tau$  administered orally induces a higher level of blood OAS activity than that induced by i.p. injection. In particular, the orally-induced blood OAS levels were higher than the blood OAS levels induced by i.p. injection at IFN- $\tau$  dosages of greater than about  $10^3$  U and at post administration times of greater than about 8 hours.

A comparative study was done to measure the effect of oral administration of MuIFN- $\alpha$  on blood OAS levels. In this study, ICR mice were treated with varying concentrations (0,  $10^2$ ,  $10^3$  and  $10^4$  IU) of MuIFN- $\alpha$  by either the p.o. or i.p. route. OAS activity in blood obtained 16 hours after MuIFN- $\alpha$  administration was assayed. The results are shown in Fig. 4, where each bar represents the average  $\pm$  S.E. of one experiment (3 mice) of two performed, with similar results.

Fig. 4 is a bar graph showing induction of blood OAS activity, expressed as a percentage of control (see description of control in Fig. 1 above), following administration of MuIFN $\alpha$  (0,  $10^2$ ,  $10^3$  and  $10^4$  IU) given orally or via intraperitoneal injection. The level of OAS activity was increased dose-dependently by either route of administration, with i.p. injection resulting in better induction of blood OAS activity than p.o. administration. This result is the opposite of that observed with IFN- $\tau$ , where oral administration of IFN- $\tau$  achieved a higher blood OAS level than intraperitoneal injection of IFN- $\tau$ . Moreover, the body temperature of mice rose slightly when MuIFN- $\alpha$  was administered, but not when OvIFN- $\tau$  was used (data not shown).

### III. Utility

#### A. Treatment of Conditions Responsive to IFN- $\tau$

As noted above, IFN- $\tau$  has biological activity as an antiviral agent, an anti-proliferative agent, and in treatment of autoimmune disorders (see for example  
5 U.S. Patent Nos. 5,958,402; 5,942,223; 6,060,450; 6,372,206, which are incorporated by reference herein). Accordingly, the invention contemplates oral administration of IFN- $\tau$  for treatment of any condition responsive to IFN- $\tau$  when administered via injection. Conditions and diseases which may be treated using methods of the present invention include autoimmune, inflammatory, proliferative  
10 and hyperproliferative diseases, as well as immunologically-mediated diseases.

In particular, methods of the present invention are advantageous for treating conditions relating to immune system hypersensitivity. There are four types of immune system hypersensitivity (Clayman, C.B., Ed., AMERICAN MEDICAL  
ASSOCIATION ENCYCLOPEDIA OF MEDICINE, Random House, New York, N.Y., (1991)):

15 Type I, or immediate/anaphylactic hypersensitivity, is due to mast cell degranulation in response to an allergen (e.g., pollen), and includes asthma, allergic rhinitis (hay fever), urticaria (hives), anaphylactic shock, and other illnesses of an allergic nature. Type II, or autoimmune hypersensitivity, is due to antibodies that are directed against perceived "antigens" on the body's own cells.  
20 Type III hypersensitivity is due to the formation of antigen/antibody immune complexes which lodge in various tissues and activate further immune responses, and is responsible for conditions such as serum sickness, allergic alveolitis, and the large swellings that sometimes form after booster vaccinations. Type IV hypersensitivity is due to the release of lymphokines from sensitized T-cells, which  
25 results in an inflammatory reaction. Examples include contact dermatitis, the rash of measles, and "allergic" reactions to certain drugs.

The mechanisms by which certain conditions may result in hypersensitivity in some individuals are generally not well understood, but may involve both genetic and extrinsic factors. For example, bacteria, viruses or drugs may play a  
30 role in triggering an autoimmune response in an individual who already has a genetic predisposition to the autoimmune disorder. It has been suggested that the incidence of some types of hypersensitivity may be correlated with others. For

example, it has been proposed that individuals with certain common allergies are more susceptible to autoimmune disorders.

Autoimmune disorders may be loosely grouped into those primarily restricted to specific organs or tissues and those that affect the entire body.

5 Examples of organ-specific disorders (with the organ affected) include multiple sclerosis (myelin coating on nerve processes), type I diabetes mellitus (pancreas), Hashimoto's thyroiditis (thyroid gland), pernicious anemia (stomach), Addison's disease (adrenal glands), myasthenia gravis (acetylcholine receptors at neuromuscular junction), rheumatoid arthritis (joint lining), uveitis (eye), psoriasis  
10 (skin), Guillain-Barré Syndrome (nerve cells) and Grave's disease (thyroid). Systemic autoimmune diseases include systemic lupus erythematosus and dermatomyositis.

Other examples of hypersensitivity disorders include asthma, eczema, atopic dermatitis, contact dermatitis, other eczematous dermatitides, seborrheic  
15 dermatitis, rhinitis, Lichen planus, Pemphigus, bullous Pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous eosinophilias, Alopecia areata, atherosclerosis, primary biliary cirrhosis and nephrotic syndrome. Related diseases include intestinal inflammations, such as Coeliac disease, proctitis, eosinophilia gastroenteritis, mastocytosis, inflammatory bowel disease,  
20 Crohn's disease and ulcerative colitis, as well as food-related allergies.

Autoimmune diseases particularly amenable for treatment using the methods of the present invention include multiple sclerosis, type I (insulin dependent) diabetes mellitus, lupus erythematosus, amyotrophic lateral sclerosis, Crohn's disease, rheumatoid arthritis, stomatitis, asthma, uveitis, allergies and  
25 psoriasis.

Methods of the present invention may be used to therapeutically treat and thereby alleviate autoimmune disorders such as those discussed above.

In another embodiment, the methods of the invention are used to treat conditions associated with viral infection. The antiviral activity of IFN- $\tau$  has broad  
30 therapeutic applications without the toxic effects that are usually associated with IFN $\alpha$ s, and IFN- $\tau$  exerts its therapeutic activity without adverse effects on the cells. The relative lack of cytotoxicity of IFN- $\tau$  makes it extremely valuable as an *in vivo*

therapeutic agent and sets IFN- $\tau$  apart from most other known antiviral agents and all other known interferons.

Formulations containing IFN- $\tau$  can be orally-administered to inhibit viral replication. Examples of specific viral diseases which may be treated by orally-administered IFN $\tau$  include, but are not limited to, hepatitis A, hepatitis B, hepatitis C, non-A, non-B, non-C hepatitis, Epstein-Barr viral infection, HIV infection, herpes virus (EB, CML, herpes simplex), papilloma, poxvirus, picorna virus, adeno virus, rhino virus, HTLV I, HTLV II, and human rotavirus.

In another embodiment, the methods of the invention are contemplated for treatment of conditions characterized by hyperproliferation. IFN- $\tau$  exhibits potent anticellular proliferation activity. Accordingly, a method of inhibiting cellular growth by orally administering IFN- $\tau$  is contemplated, in order to inhibit, prevent, or slow uncontrolled cell growth.

Examples of specific cell proliferation disorders which may be treated by orally-administered IFN- $\tau$  include, but are not limited to, hairy cell leukemia, Kaposi's Sarcoma, chronic myelogenous leukemia, multiple myeloma, superficial bladder cancer, skin cancer (basal cell carcinoma and malignant melanoma), renal cell carcinoma, ovarian cancer, low grade lymphocytic and cutaneous T cell lymphoma, and glioma.

In addition to the uses of the methods of the present invention detailed above, it will be appreciated that the methods may be applied to the treatment of a variety of immune system disorders suffered by domesticated and wild animals. For example, hypothyroidism in dogs typically results from a progressive destruction of the thyroid, which may be associated with lymphocytic thyroiditis (Kemppainen, R.J., and Clark, T.P., *Vet Clin N Am Small Anim Pract* 24(3):467-476, (1994)). Lymphocytic thyroiditis, which resembles Hashimoto's thyroiditis in humans, is thought to be an autoimmune disorder. According to the guidance presented herein, hypothyroidism due to lymphocytic thyroiditis in dogs may be treated with IFN- $\tau$  as described above.

Another type of autoimmune disorder in dogs that may be alleviated by treatment with IFN- $\tau$  is characterized by antinuclear antibody (ANA) positivity, pyrexia and seronegative arthritis (Day, M.J., *et al.*, *Clin Immunol Immunopathol* 35(1):85-91,(1985)). Immune-mediated thrombocytopenia (ITP; Kristensen, A.T.,

et al., *J Vet Intern Med* 8(1):36-39, (1994); Werner, L.L., et al., *Vet Immunol Immunopathol* 8(1-2):183-192, (1985)), systemic lupus erythematosus (Kristensen, et al., 1994), and leukopenia and Coomb's positive hemolytic anemia (Werner, et al., 1985), may also be amenable to treatment using methods of the present invention.

#### B. Formulations and Dosages

Oral preparations containing IFN- $\tau$  can be formulated according to known methods for preparing pharmaceutical compositions. In general, the IFN- $\tau$  therapeutic compositions are formulated such that an effective amount of the IFN- $\tau$  is combined with a suitable additive, carrier and/or excipient in order to facilitate effective oral administration of the composition. For example, tablets and capsules containing IFN- $\tau$  may be prepared by combining IFN- $\tau$  (e.g., lyophilized IFN- $\tau$  protein) with additives such as pharmaceutically acceptable carriers (e.g., lactose, corn starch, microcrystalline cellulose, sucrose), binders (e.g., alpha-form starch, methylcellulose, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone), disintegrating agents (e.g., carboxymethylcellulose calcium, starch, low substituted hydroxy-propylcellulose), surfactants (e.g., Tween 80, polyoxyethylene-polyoxypropylene copolymer), antioxidants (e.g., L-cysteine, sodium sulfite, sodium ascorbate), lubricants (e.g., magnesium stearate, talc), or the like.

Further, IFN- $\tau$  polypeptides of the present invention can be mixed with a solid, pulverulent or other carrier, for example lactose, saccharose, sorbitol, mannitol, starch, such as potato starch, corn starch, millopectine, cellulose derivative or gelatine, and may also include lubricants, such as magnesium or calcium stearate, or polyethylene glycol waxes compressed to the formation of tablets. By using several layers of the carrier or diluent, tablets operating with slow release can be prepared.

Liquid preparations for oral administration can be made in the form of elixirs, syrups or suspensions, for example solutions containing from about 0.1% to about 30% by weight of IFN- $\tau$ , sugar and a mixture of ethanol, water, glycerol, propylene, glycol and possibly other additives of a conventional nature.

An orally-active IFN- $\tau$  pharmaceutical composition is administered in a therapeutically-effective amount to an individual in need of treatment. The dose may vary considerably and is dependent on factors such as the seriousness of the disorder, the age and the weight of the patient, other medications that the patient may be taking and the like. This amount or dosage is typically determined by the attending physician. The dosage will typically be between about  $1 \times 10^4$  and  $1 \times 10^9$  units/day, more preferably between  $1 \times 10^5$  and  $1 \times 10^8$  units/day, preferably between about  $1 \times 10^6$  and  $1 \times 10^7$  units/day. In one specific embodiment, IFN- $\tau$  is administered orally at a dosage of greater than about  $1 \times 10^4$  units/day, preferably of greater than about  $1 \times 10^6$  units/day, more preferably greater than about  $1 \times 10^8$  units/day.

Disorders requiring a steady elevated level of IFN- $\tau$  in plasma will benefit from administration as often as about every two to four hours, while other disorders, such as multiple sclerosis, may be effectively treated by administering a therapeutically-effective dose at less frequent intervals, e.g., once every 48 hours. The rate of administration of individual doses is typically adjusted by an attending physician to enable administration of the lowest total dosage while alleviating the severity of the disease being treated.

Once improvement of a patient's condition has occurred, a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained.

As noted above, oral administration of IFN- $\tau$  is prescribed along with a defined food/water intake regimen. It will be appreciated that the food/water intake regimen selected for the supporting studies described with respect to Figs. 1A-3B are merely exemplary. The invention contemplated that food and/or water can be withheld for a variety of times prior to dosing with the protein, ranging from more or less than the 6 hours exemplified here. In a preferred embodiment, food and/or water are withheld for at least about one hour prior to oral administration of IFN- $\tau$ , more preferably are withheld for at least about two hours, still more preferably for at least about six hours.

It will, of course, be understood that the oral administration of IFN- $\tau$  in accord with the invention may be used in combination with other therapies. For



example, IFN- $\tau$  can be accompanied by administration of an antigen against which an autoimmune response is directed. Examples include co-administration of myelin basic protein and IFN- $\tau$  to treat multiple sclerosis; collagen and IFN- $\tau$  to treat rheumatoid arthritis, and acetylcholine receptor polypeptides and IFN- $\tau$  to treat myasthenia gravis.

Furthermore, IFN- $\tau$  may be orally administered with known immunosuppressants, such as steroids, to treat autoimmune diseases such as multiple sclerosis. The immunosuppressants may act synergistically with IFN- $\tau$  and result in a more effective treatment that could be obtained with an equivalent dose of IFN- $\tau$  or the immunosuppressant alone.

Similarly, in a treatment for a cancer or viral disease, IFN- $\tau$  may be administered in conjunction with, e.g., a therapeutically effective amount of one or more chemotherapy agents such as busulfan, 5-fluorouracil (5-FU), zidovudine (AZT), leucovorin, melphalan, prednisone, cyclophosphamide, dacarbazine, cisplatin, dipyridamole, and the like.

#### IV. Examples

The following example illustrates but in no way is intended to limit the present invention.

#### Example 1

##### Method of Oral Administration

Pathogen-free 5-week-old female mice of the ICR, BALB/c, C57BL/9, NZW/N and SJL/J strains were purchased from Japan SLC, Inc., Hamamatsu. The mice were reared one week in the laboratory before experiments.

Recombinant ovine IFN- $\tau$  (OvIFN- $\tau$ ) was obtained from Pepgen Corporation (Alameda, CA). The IFN belongs to the subtype of OvIFN- $\tau$ 1. The preparation used in this study had a specific activity of  $5 \times 10^8$  units (U)/mg protein as assayed in MDBK cells challenged with VSV and standardized against human IFN- $\alpha$ . Natural murine IFN- $\alpha$  (MuIFN- $\alpha$ ) was supplied by Sumitomo Pharmaceutical Co. (Osaka, Japan), whose specific activity was  $1 \times 10^8$  international units (IU)/mg protein.

For administration to the mice, IFN- $\tau$  was dissolved in a solution containing 10% maltose. Samples of 0.2 ml were administered to mice (6-week-old females)

by either peroral (p.o.) treatment or intraperitoneal (i.p.) injection. When given orally, the samples were introduced directly into the upper part of the stomach using a 20 gauge oral feeding needle. Before the administration, mice were deprived of both food and drink for 6 hours, starting at 1 pm and ending at 7 pm.

- 5 After the fasting, IFN was administered by either the p.o. or i.p. route and food and drink were given at 6 hours. Then, whole blood was obtained from the heart at 24 hours.

10 The 2',5'-oligoadenylate synthetase (OAS) activity in whole blood was assayed with Eiken's 2-5A RIA kit. Diluted blood was mixed with poly:C-agarose gel, ATP was added after washing the gel, and the 2-5A produced was assayed by the RIA method (Shindo, M., *et al.*, 1988). The assays were performed twice in each sample. For the estimation of the level of blood OAS, at least three mice were used.

## IT IS CLAIMED:

1. A composition for use in treating a condition responsive to interferon- $\tau$ , comprising an oral dosage form of interferon- $\tau$ , said dosage form administered to  
5 a subject in a fasted state to achieve an increased level of 2',5'-oligoadenylate synthetase in the blood relative to the level of 2',5'-oligoadenylate synthetase in the blood obtained after oral administration of interferon- $\tau$  to a patient in a non-fasted state.

10 2. The composition according to claim 1, wherein said interferon- $\tau$  is ovine or bovine interferon- $\tau$ .

3. The composition according to claim 1 or claim 1, wherein said interferon- $\tau$  has a sequence corresponding to the amino acid sequence presented  
15 as SEQ ID NO:2.

4. The composition according to any one of the preceding claims, wherein said orally administering is by oral administration of a solid dosage form or a liquid dosage form.

20 5. The composition according to claim 4, wherein said orally administering is at a dose of at least about  $1 \times 10^4$  Units/day.

6. The composition according to claim 5, wherein said condition  
25 responsive to interferon- $\tau$  is an autoimmune condition, a viral infection, or a disorder characterized by cellular proliferation.

7. Use of a composition for the manufacture of a medicament for oral administration of interferon- $\tau$  to a subject in a fasted state to achieve an increased  
30 level of 2',5'-oligoadenylate synthetase in the blood relative to the level of 2',5'-oligoadenylate synthetase in the blood obtained after oral administration of interferon- $\tau$  to a fed subject.

8. The use according to claim 7, wherein said water is withheld from said subject.

5 9. The use according claim 7 or claim 8, wherein said fasted state is achieved by withholding food from said subject for at least one hour prior to oral administration.

10 10. The use according claim 7 or claim 8, wherein said fasted state is achieved by withholding food from said subject for at least two hours prior to oral administration.

15 11. The use according claim 7 or claim 8, wherein said fasted state is achieved by withholding food from said subject for at least six hours prior to oral administration.

12. The use according to any one of claims 7-11, wherein said interferon- $\tau$  is ovine or bovine interferon- $\tau$ .





20 13. The use according to claim 12, wherein said interferon- $\tau$  has an amino acid sequence corresponding to the sequence presented as SEQ ID NO:2.

14. The use according to claim 12, wherein said medicament is a solid dosage form or a liquid dosage form.


25 15. The use according to claim 14, wherein said dosage form includes a dose of interferon- $\tau$  of at least about  $1 \times 10^4$  Units/day.

16. The use according to claim 14 for treatment of an autoimmune condition, a viral infection, or a disorder characterized by cellular proliferation.


1/5


**Fig. 1A****Fig. 1B****Fig. 1C****Fig. 1D**

2/5

**Fig. 2**


3/5

**Fig. 3A**

**Fig. 3B**



5/5

**Fig. 4**

## SEQUENCE LISTING

&lt;110&gt; Pepgen Corporation

&lt;120&gt; Oral Administration of Interferon-tau

&lt;130&gt; 55600.8009.WO0

&lt;140&gt; Not Yet Assigned

&lt;141&gt; Filed Herewith

&lt;150&gt; US 60/349,658

&lt;151&gt; 2002-01-16

&lt;160&gt; 3

&lt;170&gt; FastSEQ for Windows Version 4.0

&lt;210&gt; 1

&lt;211&gt; 516

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic gene encoding ovine interferon-tau

&lt;221&gt; CDS

&lt;222&gt; (1)...(516)

&lt;223&gt; amino acid sequence encoded

&lt;400&gt; 1

tgc	tac	ctg	tcg	cga	aaa	ctg	atg	ctg	gac	gct	cga	gaa	aat	tta	aaa	48
Cys	Tyr	Leu	Ser	Arg	Lys	Leu	Met	Leu	Asp	Ala	Arg	Glu	Asn	Leu	Lys	
1				5					10					15		

ctg	ctg	gac	cgt	atg	aat	cga	ttg	tct	ccg	cac	agc	tgc	ctg	caa	gac	96
Leu	Leu	Asp	Arg	Met	Asn	Arg	Leu	Ser	Pro	His	Ser	Cys	Leu	Gln	Asp	
			20					25					30			

cgg	aaa	gac	ttc	ggc	ctg	ccg	cag	gaa	atg	gtt	gaa	ggc	gac	caa	ctg	144
Arg	Lys	Asp	Phe	Gly	Leu	Pro	Gln	Glu	Met	Val	Glu	Gly	Asp	Gln	Leu	
		35					40					45				

caa	aaa	gac	caa	gct	ttc	ccg	gta	ctg	tat	gaa	atg	ctg	cag	cag	tct	192
Gln	Lys	Asp	Gln	Ala	Phe	Pro	Val	Leu	Tyr	Glu	Met	Leu	Gln	Gln	Ser	
	50					55				60						

ttc	aac	ctg	ttc	tac	act	gaa	cat	tct	tcg	gcc	gct	tg	gac	act	act	240
Phe	Asn	Leu	Phe	Tyr	Thr	Glu	His	Ser	Ser	Ala	Ala	Trp	Asp	Thr	Thr	
	65				70					75					80	

ctt	cta	gaa	caa	ctg	tgc	act	ggc	ctg	caa	cag	caa	ctg	gac	cat	ctg	288
Leu	Leu	Glu	Gln	Leu	Cys	Thr	Gly	Leu	Gln	Gln	Gln	Leu	Asp	His	Leu	
			85					90						95		

gac	act	tgc	cgt	ggc	cag	gtt	atg	ggc	gaa	gaa	gac	tct	gaa	ctg	ggc	336
Asp	Thr	Cys	Arg	Gly	Gln	Val	Met	Gly	Glu	Glu	Asp	Ser	Glu	Leu	Gly	
			100					105					110			

aac	atg	gat	ccg	atc	gtt	act	gtt	aaa	aaa	tat	ttc	cag	ggc	atc	tac	384
Asn	Met	Asp	Pro	Ile	Val	Thr	Val	Lys	Lys	Tyr	Phe	Gln	Gly	Ile	Tyr	
		115					120					125				

gac tac ctg cag gaa aaa ggt tac tct gac tgc gct tgg gaa atc gta 432  
 Asp Tyr Leu Gln Glu Lys Gly Tyr Ser Asp Cys Ala Trp Glu Ile Val  
 130 135 140

cgc gtt gaa atg atg cgg gcc ctg act gtg tcg act act ctg caa aaa 480  
 Arg Val Glu Met Met Arg Ala Leu Thr Val Ser Thr Thr Leu Gln Lys  
 145 150 155 160

cgg tta act aaa atg ggt ggt gac ctg aat tct ccg 516  
 Arg Leu Thr Lys Met Gly Gly Asp Leu Asn Ser Pro  
 165 170

<210> 2  
 <211> 172  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> amino acid encoded by SEQ ID NO:1

<400> 2  
 Cys Tyr Leu Ser Arg Lys Leu Met Leu Asp Ala Arg Glu Asn Leu Lys  
 1 5 10 15  
 Leu Leu Asp Arg Met Asn Arg Leu Ser Pro His Ser Cys Leu Gln Asp  
 20 25 30  
 Arg Lys Asp Phe Gly Leu Pro Gln Glu Met Val Glu Gly Asp Gln Leu  
 35 40 45  
 Gln Lys Asp Gln Ala Phe Pro Val Leu Tyr Glu Met Leu Gln Gln Ser  
 50 55 60  
 Phe Asn Leu Phe Tyr Thr Glu His Ser Ser Ala Ala Trp Asp Thr Thr  
 65 70 75 80  
 Leu Leu Glu Gln Leu Cys Thr Gly Leu Gln Gln Gln Leu Asp His Leu  
 85 90 95  
 Asp Thr Cys Arg Gly Gln Val Met Gly Glu Glu Asp Ser Glu Leu Gly  
 100 105 110  
 Asn Met Asp Pro Ile Val Thr Val Lys Lys Tyr Phe Gln Gly Ile Tyr  
 115 120 125  
 Asp Tyr Leu Gln Glu Lys Gly Tyr Ser Asp Cys Ala Trp Glu Ile Val  
 130 135 140  
 Arg Val Glu Met Met Arg Ala Leu Thr Val Ser Thr Thr Leu Gln Lys  
 145 150 155 160  
 Arg Leu Thr Lys Met Gly Gly Asp Leu Asn Ser Pro  
 165 170

<210> 3  
 <211> 172  
 <212> PRT  
 <213> Ovis aries

<400> 3  
 Cys Tyr Leu Ser Arg Lys Leu Met Leu Asp Ala Arg Glu Asn Leu Lys  
 1 5 10 15  
 Leu Leu Asp Arg Met Asn Arg Leu Ser Pro His Ser Cys Leu Gln Asp  
 20 25 30  
 Arg Lys Asp Phe Gly Leu Pro Gln Glu Met Val Glu Gly Asp Gln Leu  
 35 40 45  
 Gln Lys Asp Gln Ala Phe Pro Val Leu Tyr Glu Met Leu Gln Gln Ser  
 50 55 60  
 Phe Asn Leu Phe Tyr Thr Glu His Ser Ser Ala Ala Trp Asp Thr Thr  
 65 70 75 80  
 Leu Leu Glu Gln Leu Cys Thr Gly Leu Gln Gln Gln Leu Asp His Leu  
 85 90 95  
 Asp Thr Cys Arg Gly Gln Val Met Gly Glu Glu Asp Ser Glu Leu Gly  
 100 105 110

Asn	Met	Asp	Pro	Ile	Val	Thr	Val	Lys	Lys	Tyr	Phe	Gln	Gly	Ile	Tyr
		115					120					125			
Asp	Tyr	Leu	Gln	Glu	Lys	Gly	Tyr	Ser	Asp	Cys	Ala	Trp	Glu	Ile	Val
	130					135					140				
Arg	Val	Glu	Met	Met	Arg	Ala	Leu	Thr	Val	Ser	Thr	Thr	Leu	Gln	Lys
145					150					155					160
Arg	Leu	Thr	Lys	Met	Gly	Gly	Asp	Leu	Asn	Ser	Pro				
				165					170						

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
31 July 2003 (31.07.2003)

PCT

(10) International Publication Number  
**WO 2003/061728 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 45/00**,  
38/00, C07K 17/00

(21) International Application Number:  
PCT/US2003/001596

(22) International Filing Date: 16 January 2003 (16.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/349,658 16 January 2002 (16.01.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: **PEPGEN CORPORATION** [US/US]; Suite B, 1255 Harbor Bay Parkway, Alameda, CA 94502 (US).

**Published:**

— with international search report

(72) Inventors: **SOKAWA, Yoshihiro**; Department of Bio-Technology, Kyoto Institute of Technology, Kyoto 606 (JP). **LIU, Chih-Ping**; 1483 Sutter Street #1705, San Francisco, CA 94109 (US).

(88) Date of publication of the international search report:  
31 December 2003

(74) Agents: **MOHR, Judy, M. et al.**; Perkins Coie LLP, P.O. Box 2168, Menlo Park, CA 94026 (US).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **ORAL ADMINISTRATION OF INTERFERON-TAU**

(57) Abstract: A method of administering interferon- $\tau$  to a subject subsequent to a defined food and/or water intake regimen is described. The method comprises administering orally to the subject, subsequent to fasting and/or fasting combined with a controlled or absence of fluid intake, an amount of interferon- $\tau$  that is effective to achieve an increased level of 2'5'-oligoadenylate synthetase (OAS) activity in whole blood relative to that achieved from oral administration to a subject also treated with interferon- $\tau$  but not held to the defined food and/or water intake regimen.

**WO 2003/061728 A3**

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/01596

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(7) : A61K 45/00, 38/00; C07K 17/00 US CL : 424/85.2; 514/2; 530/351 According to International Patent Classification (IPC) or to both national classification and IPC																				
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/85.2; 514/2; 530/351  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched None  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet																				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>																				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
X	US 6,060,450 A (SOOS et al.) 09 May 2000 (09.05.00), see in particular columns 15, and 21-22.	1-11																		
X	US 5,906,816 A (SOOS et al.) 25 May 1999 (25.05.99), see columns 15 and 20.	1-11																		
X	SOOS, J. M. et al. Oral feeding of interferon tau can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis. J. Neuroimmunol. May 1997, Vol. 75, No. 1-2, pages 43-50, see entire document.	1-11																		
X	US 5,738,845 A (IMAKAWA) 14 April 1998 (14.04.98), see entire document and especially columns 27-28, and 95-96.	1-11																		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"><tr><td>* Special categories of cited documents:</td><td>"T"</td><td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>"A" document defining the general state of the art which is not considered to be of particular relevance</td><td>"X"</td><td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>"E" earlier application or parent published on or after the international filing date</td><td>"Y"</td><td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>"&amp;"</td><td>document member of the same patent family</td></tr><tr><td>"O" document referring to an oral disclosure, use, exhibition or other means</td><td></td><td></td></tr><tr><td>"P" document published prior to the international filing date but later than the priority date claimed</td><td></td><td></td></tr></table>			* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"E" earlier application or parent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family	"O" document referring to an oral disclosure, use, exhibition or other means			"P" document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
"E" earlier application or parent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family																		
"O" document referring to an oral disclosure, use, exhibition or other means																				
"P" document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 07 August 2003 (07.08.2003)		Date of mailing of the international search report 09 SEP 2003																		
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230		Authorized officer Anne Marie S. Wehbe Telephone No. 703-308-1235																		

Form PCT/ISA/210 (second sheet) (July 1998)

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/01596

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claim Nos.: 12-16  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

# INTERNATIONAL SEARCH REPORT

PCT/US03/01596

## Continuation of B. FIELDS SEARCHED Item 3:

DIALOG-Medline, Embase, Cancerlit, Scisearch, Biosis; BRS/EAST-USPatfull, EPO, JPO, Derwint, PG-PUBs  
search terms: interferon tau, oral, 2'-5' oligoadenylate synthetase

Form PCT/ISA/210 (second sheet) (July 1998)



(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
31 July 2003 (31.07.2003)

PCT

(10) International Publication Number  
**WO 2003/061728 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 45/00**,  
38/00, C07K 17/00

(21) International Application Number:  
PCT/US2003/001596

(22) International Filing Date: 16 January 2003 (16.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/349,658 16 January 2002 (16.01.2002) US

(71) Applicant: **PEPGEN CORPORATION** [US/US]; Suite  
B, 1255 Harbor Bay Parkway, Alameda, CA 94502 (US).

(72) Inventors: **SOKAWA, Yoshihiro**; Department of  
Bio-Technology, Kyoto Institute of Technology, Kyoto  
606 (JP). **LIU, Chih-Ping**; 1483 Sutter Street #1705, San  
Francisco, CA 94109 (US).

(74) Agents: **MOHR, Judy, M. et al.**; Perkins Coie LLP, P.O.  
Box 2168, Menlo Park, CA 94026 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,  
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,  
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- with amended claims and statement

(88) Date of publication of the international search report:  
31 December 2003

Date of publication of the amended claims and statement:  
8 April 2004

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 2003/061728 A3**

(54) Title: ORAL ADMINISTRATION OF INTERFERON-TAU

(57) Abstract: A method of administering interferon- $\tau$  to a subject subsequent to a defined food and/or water intake regimen is described. The method comprises administering orally to the subject, subsequent to fasting and/or fasting combined with a controlled or absence of fluid intake, an amount of interferon- $\tau$  that is effective to achieve an increased level of 2'5'-oligoadenylate synthetase (OAS) activity in whole blood relative to that achieved from oral administration to a subject also treated with interferon- $\tau$  but not held to the defined food and/or water intake regimen.

## AMENDED CLAIMS

[received by the International Bureau on 08 October 2003 (08.10.03);  
Claims 3, 8-12 amended; remaining claims unchanged (2 pages)]

## IT IS CLAIMED:

1. A composition for use in treating a condition responsive to interferon- $\tau$ , comprising an oral dosage form of interferon- $\tau$ , said dosage form  
5 administered to a subject in a fasted state to achieve an increased level of 2',5'-oligoadenylate synthetase in the blood relative to the level of 2',5'-oligoadenylate synthetase in the blood obtained after oral administration of interferon- $\tau$  to a patient in a non-fasted state.
- 10 2. The composition according to claim 1, wherein said interferon- $\tau$  is ovine or bovine interferon- $\tau$ .
3. The composition according to claim 1 or claim 2, wherein said interferon- $\tau$  has a sequence corresponding to the amino acid sequence presented as  
15 SEQ ID NO:2.
4. The composition according to any one of the preceding claims, wherein said orally administering is by oral administration of a solid dosage form or a liquid dosage form.  
20
5. The composition according to claim 4, wherein said orally administering is at a dose of at least about  $1 \times 10^4$  Units/day.
6. The composition according to claim 5, wherein said condition responsive to  
25 interferon- $\tau$  is an autoimmune condition, a viral infection, or a disorder characterized by cellular proliferation.
7. Use of a composition for the manufacture of a medicament for oral  
30 administration of interferon- $\tau$  to a subject in a fasted state to achieve an increased level of 2',5'-oligoadenylate synthetase in the blood relative to the level of 2',5'-oligoadenylate synthetase in the blood obtained after oral administration of interferon- $\tau$  to a fed subject.

8. The use according claim 7, wherein said fasted state is achieved by withholding food from said subject for at least one hour prior to oral administration.
- 5
9. The use according claim 7, wherein said fasted state is achieved by withholding food from said subject for at least two hours prior to oral administration.
- 10
10. The use according claim 7, wherein said fasted state is achieved by withholding food from said subject for at least six hours prior to oral administration.
11. The use according to any one of claims 7 to 10, wherein said fasted state
- 15 is a fasted state also excluding water.
12. The use according to any one of claims 7-10, wherein said interferon- $\tau$  is ovine or bovine interferon- $\tau$ .
- 20
13. The use according to claim 12, wherein said interferon- $\tau$  has an amino acid sequence corresponding to the sequence presented as SEQ ID NO:2.
14. The use according to claim 12, wherein said medicament is a solid dosage form or a liquid dosage form.
- 25
15. The use according to claim 14, wherein said dosage form includes a dose of interferon- $\tau$  of at least about  $1 \times 10^4$  Units/day.
16. The use according to claim 14 for treatment of an autoimmune condition, a
- 30 viral infection, or a disorder characterized by cellular proliferation.

**STATEMENT UNDER ARTICLE 19 (1)**

The enclosed replacement sheets 18-19, for replacement of original sheets 18-19 of the above-referenced application, amend the claims as described:

Claims 1-2, 4-7, and 13-16 are unchanged.

Claim 3 is amended in its dependency.

Claim 8 corresponds to original claim 9 and is amended in its dependency.

Claim 9 corresponds to original claim 10 and is amended in its dependency.

Claim 10 corresponds to original claim 11 and is amended in its dependency.

Claim 11 corresponds to original claim 8 and is rewritten to describe that the fasted state is a fasted state including water.

Claim 12 is amended in its dependency.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**